en · de · es · fr · pt
compound-index.peptides9002.com › Blog › Melanotan-2 Identity And Regulatory Status — Explained

Melanotan-2 Identity And Regulatory Status — Explained

By Editorial Desk · published 2026-01-13 · last reviewed 2026-02-07 · Blog

A practical reference on Melanotan II: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-02-07 and is reviewed periodically as new material appears.

Melanotan-2 Identity And Regulatory Status

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.

Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Handling, Measurement, and Regulatory Context

Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.

Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.

Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.

Melanotan-2 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideAnalogue of alpha-melanocyte-stimulating hormone
Common synonymsMT-II; melanotan 2No internationally accepted non-proprietary name
Typical presentationLyophilised powder in a sealed vialOften supplied alongside a separate diluent
Regulatory statusUnapproved therapeutic substanceCustoms seizure reported in several jurisdictions
Reported route in useSubcutaneous injectionSelf-administered outside clinical settings

Identity and Chemical Background

Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.

The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.

Related pages on this site

Regulatory Status and Literature Discussion

Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.

Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.

Background from the literature

Targeted screening may be appropriate in a number of situations where hypothyroidism is common: other autoimmune diseases, a strong family history of thyroid disease, those who have received radioiodine or other radiation therapy to the neck, those who have previously undergone thyroid surgery, those with an abnormal thyroid examination, those with psychiatric disorders, people taking amiodarone or lithium, and those with a number of health conditions (such as certain heart and skin conditions). Yearly thyroid function tests are recommended in people with Down syndrome, as they are at higher risk of thyroid disease. Guidelines for England and Wales from the National Institute for Health and Care Excellence (NICE) recommend testing for thyroid disease in people with type 1 diabetes and new-onset atrial fibrillation, and suggests testing in those with depression or unexplained anxiety (all ages), in children with abnormal growth, or unexplained change in behavior or school performance. NICE also recommends screening for celiac disease in people with a diagnosis of autoimmune thyroid disease.

Khloé Alexandra Kardashian (; born June 27, 1984) is an American media personality, socialite, and businesswoman. She rose to fame starring with her family in the reality television series Keeping Up with the Kardashians from 2007 to 2021. Its success led to the creation of spin-offs, including Kourtney and Khloé Take Miami (2009–2013) and Kourtney and Khloé Take The Hamptons (2014–2015). Following the ending of their previous show, she and her family began starring on Hulu's The Kardashians in 2022. From September 2009 to December 2016, Kardashian was married to basketball player Lamar Odom, whom she married one month after they first met. They starred in their own reality television series, Khloé & Lamar (2011–2012). In 2009, Kardashian participated in the second season of The Celebrity Apprentice, finishing 10th of 16 candidates after being fired by Donald Trump. In 2012, she co-hosted the second season of the American adaptation of The X Factor with actor Mario Lopez. In 2016, Kardashian hosted her own talk show, Kocktails with Khloé. She starred in and produced health and fitness docu-series Revenge Body with Khloé Kardashian from 2017 to 2019. In 2025, she began hosting her own weekly podcast called Khloe in Wonderland. Kardashian has been involved in the retail and fashion industries with her sisters Kourtney and Kim. They have launched several clothing collections and fragrances, and additionally released the book Kardashian Konfidential in 2010. The Dash boutique employees starred in their own short-lived reality television series, Dash Dolls (2015).

== Chemical structure == Malacidins are macrocycle lipopeptides. The 2018 paper described two chemicals in the malacidin family, differing only by a methylene at their lipid tails. Their peptide cores include four non-proteinogenic amino acids. The name "malacidin" is derived from the abbreviation of metagenomic acidic lipopeptide antibiotic and the suffix -cidin.

Sources: en.wikipedia.org

Reference notes

== Further reading == De Vito, D.; Weber, J.; Merbach, A. E. “Calculated Volume and Energy Profiles for Water Exchange on t2g 6 Rhodium(III) and Iridium(III) Hexaaquaions: Conclusive Evidence for an Ia Mechanism” Inorganic Chemistry, 2004, Volume 43, pages 858–863. doi:10.1021/ic035096n Zumdahl, Steven S. Chemical Principles, Fifth Edition. New York: Houghton Mifflin, 2005. 943–946, 957. OCLC 77760970 Harris, D., Bertolucci, M., Symmetry and Spectroscopy. 1989 New York, Dover Publications

The Gallery of Palaeontology and Comparative Anatomy was built between 1894 and 1897 by architect Ferdinand Dutert, who had built the innovative iron-framed Galerie des machines at the 1889 Paris Exposition. A new pavilion in the same style was added to the west side of the gallery; it was completed in 1961. In front of the Gallery is the Iris Garden, created in 1964, which displays 260 varieties of iris flowers, and a sculpture, "Nymph with a pitcher" (1837) by Isidore Hippolyte Brion. The sides of gallery are also decorated with sculpture; twelve relief sculptures of animals in bronze and fourteen medallions of famous biologists. The ironwork grill and stone arches over the entrance are filled with elaborate designs and sculpture of seashells. Inside the entrance is a large marble statue of an Orangutan strangling a hunter, created in 1885 by the noted animal sculptor Emmanuel Fremiet, best known for his statue of Joan of Arc on horseback on the Place des Pyramides in Paris.

=== Other ventures === Around 2013, Newell co-founded and funded Foundry10, an educational research organization. In 2018, Newell donated $20 million to the American artificial intelligence company OpenAI and acted as an informal advisor. In 2022, with Philip Sabes, Newell co-founded the neuroscience company Starfish Neuroscience to develop neural interfaces. In May 2025, Starfish announced that their first chip would be released late that year. Newell is the owner of the marine research organization Inkfish, which owns several ships and submarines. In November 2022, Inkfish purchased the Hadal Exploration System, a private deep-sea exploration platform, from the undersea explorer Victor Vescovo. In August 2025, Newell acquired the privately owned yacht manufacturer Oceanco.

Sources: en.wikipedia.org

Reference notes

== Further reading == Price, Nicholas C; Stevens, Lewis (1996). Principi di enzimologia [Principles of enzymology] (in Italian). A. Delfino. ISBN 978-88-7287-100-3. OCLC 879866185. Mazzucato, Fernando; Giovagnoni, Andrea (2019). Manuale di tecnica, metodologia e anatomia radiografica tradizionali [Manual of traditional radiographic technique, methodology and anatomy] (in Italian). Piccin. ISBN 978-88-299-2959-7. OCLC 1141547603. Torricelli, P; Antonelli, F; Ferorelli, P; Borromeo, I; Shevchenko, A; Lenzi, S; De Martino, A (March 2020). "Oral nutritional supplement prevents weight loss and reduces side effects in patients in advanced lung cancer chemotherapy". Amino Acids. 52 (3): 445–451. doi:10.1007/s00726-020-02822-7. PMID 32034492. S2CID 211053578.

Alex Browne (born 9 August 1992) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). Browne played for the Oakleigh Chargers in the TAC Cup. He was drafted by Essendon with pick 48 in the 2010 national draft and made his debut against Melbourne at the Melbourne Cricket Ground in round 11 of the 2011 AFL season. He was delisted in October 2015. His father, Murray Browne, played for Collingwood and Fitzroy in the 1980s and his mother was a cheerleader for Carlton. Browne, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension. Browne had signed for the Northern Blues in the Victorian Football League for the 2016 season before his suspension ended his 2016 season.

Historically, the illicit drug trade in Colombia had strong connections to right-wing paramilitaries like the United Self-Defenders of Colombia (AUC) and leftist guerilla groups like the Revolutionary Armed Forces of Colombia (FARC), thus US anti-drug efforts in the country overlapped with support for counterinsurgency efforts. In the late 1960s, when drug smuggling to the US from Mexico rose to a major scale, the two governments cooperated in the launch of the Mexican drug war; the market disruption gave Colombian traffickers an opportunity to fill US demand for cannabis. Until the 1970s, Colombia "had played no major role in the production and circulation of illegal drugs in the hemisphere". After a military coup in Chile in 1973 and the spread of political repression through the Southern Cone countries disrupted cocaine smuggling from Peru and Bolivia, Colombia stepped in to fill the demand for cocaine. Pressed by the US, the Colombian government, under president Misael Pastrana (1970–1974), worked with the newly formed DEA to establish the future path for the country's war on drugs. During the 1970s, the "marijuana boom" dominated Colombia's drug trade, peaking mid-decade. That soon gave way to cocaine and the rise of the infamous Medellin and Cali Cartels that grew through the 1980s and early 1990s to dominate the global cocaine market. By the end of the century, the brutal anti-drug war left the security situation in Colombia in critical condition.

== Reactions == Piperidine is widely used to convert ketones to enamines. Enamines derived from piperidine are substrates in the Stork enamine alkylation reaction. Upon treatment with calcium hypochlorite, piperidine converts to N-chloropiperidine, a chloramine with the formula C5H10NCl. The resulting chloramine undergoes dehydrohalogenation to afford the cyclic imine.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan II approved for medical use?

No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.

Where did melanotan II originate?

It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.

Why is purity a concern for unapproved peptides?

Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.

How is a sample checked for identity?

Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.

Network